News &
Events

Press Releases

Follow CatalYm’s journey and learn more
about our most recent milestones

July 16, 2024

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

- Read More

June 2, 2024

CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination

- Read More

May 23, 2024

CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

- Read More

Load MoreLoading

Meet us at the following
conferences & events

FASEB Science Research Conferences - TGF-β Superfamily

July 21 - July 25, 2024

Niagara Falls, NY, USA

Read More

World Conference on Lung Cancer 2024

Sep 7 - Sep 10, 2024

San Diego, USA

Read More

ESMO 2024

Sep 13 - Sep 17, 2024

Barcelona, Spain

Read More

WordPress Cookie Notice by Real Cookie Banner